报 告 人：Prof. Nathan J. Hillson，Principal Investigator of the U.S. DOE Agile Biofoundry 

　　报告题目：U.S. DOE Agile BioFoundry: Overview and Recent Highlights 

　　报告时间：8月16日（周五） 10:30 

　　报告地点：B301阶梯教室 

　　报告摘要： 

　　The overarching goal of the DOE Agile BioFoundry (ABF) is to enable biorefineries to achieve 50% reductions in time to bioprocess scale-up(as compared to the current average of around 10 years) by establishing a distributed BioFoundry that productionizes synthetic biology. Toward achieving this goal, the ABF has brought together domain expertise and infrastructure that is distributed across 8 U.S. National Labs (LBNL, SNL, PNNL, NREL, ANL, ORNL, LANL, and INL). This talk will introduce the ABF, and provide some research and development highlights (including work with industry) from the first 2.5 years of its operations. 

　　报告人简介： 

　　Dr. Hillson earned his Ph.D. in Biophysics from Harvard Medical School. He did his postdoctoral work in Developmental (Micro) Biology at Stanford University School of Medicine. Dr. Hillson's work has spanned the realms of the private (notably as co-founder and Chief Scientific Officer at TeselaGen Biotechnologies, Inc.) and public biotechnology sectors. As Department Head of BioDesign within the Biological Systems & Engineering Division, Dr. Hillson leads scientists and engineers within Lawrence Berkeley National Laboratory whose domain expertise spans synthetic biology, metabolic engineering, microbiology, microbial communities, software engineering, andlaboratory automation engineering. As overall Principal Investigator of the U.S. DOE Agile Biofoundry, Dr. Hillson leads an even broader group of scientists and engineers distributed across 8 U.S. DOE National Labs towards the development of a public infrastructure that enables the private sector to reduce the cost and accelerate bioprocess commercialization timelines (from conception to process scale up and deployment). This infrastructure complements discovery engines (such as the Joint Genome Insitute, to which Dr. Hillson also contributes), by enabling the discovered (yet small scale, low titer/rates/yields) pathways to be more quickly and reliably optimized and scaled. Efforts are supported by DOE-funded entities, including the DOE Agile BioFoundry, DOE Joint BioEnergy Institute, DOE Joint Genome Institute, as well as by industry-sponsored collaborations.